Biomarkers in native and transplant kidneys: Opportunities to improve prediction of outcomes in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 6, 2012, Pages 619-627

  De Serres, Sacha A ^a   Varghese, Jay C ^b   Levin, Adeera ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

biomarkers; cardiovascular events; chronic kidney disease; native kidney; progression; transplant kidney

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; 25 HYDROXYVITAMIN D; ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BICARBONATE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CALCIUM; CD30 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CREATININE; CYSTATIN C; FIBROBLAST GROWTH FACTOR 23; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANZYME B; HLA DR ANTIGEN; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PERFORIN; PHOSPHATE; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACCURACY; ALLOIMMUNITY; CALCIUM BLOOD LEVEL; CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; GENE EXPRESSION PROFILING; GRAFT DYSFUNCTION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY GRAFT; MORTALITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RESOURCE ALLOCATION; REVIEW; RISK FACTOR;

ALBUMINURIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CREATININE; DISEASE PROGRESSION; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84868193428     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835846e3     Document Type: Review

References (91)

1. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379:165-180.
2. Levin A, Stevens PE. Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol 2011; 7:446-457.
3. Weekley CC, Peralta CA. Advances in the use of multimarker panels for renal risk stratification. Curr Opin Nephrol Hypertens 2012; 21:301-308.
4. Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time (CanPREDDICT); Identifier: NCT00826319 Available from: www.clinicaltrials.gov/ct2/show/NCT00826319? term¼canpreddict&rank¼1. [Accessed May 2012]
5. Junyent M, Martinez M, Borras M, et al. Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study. BMC Nephrol 2010; 11:14.
6. Spanaus KS, Kronenberg F, Ritz E, et al. B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem 2007; 53:1264-1272.
7. Feldman HI, Appel LJ, Chertow GM, et al. The Chronic Renal Insufficiency Cohort (CRIC) study: design and methods. J Am Soc Nephrol 2003; 14 (7 Suppl 2):S148-S153.
8. Landray MJ, Emberson JR, Blackwell L, et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010; 56:1082-1094.
9. Shan Y, Zhang Q, Liu Z, et al. Prevalence and risk factors associated with chronic kidney disease in adults over 40 years: a population study from Central China. Nephrology (Carlton) 2010; 15:354-361.
10. Takamatsu N, Abe H, Tominaga T, et al. Risk factors for chronic kidney disease in Japan: a community-based study. BMC Nephrol 2009; 10:34.
11. Baumeister SE, Boger CA, Kramer BK, et al. Effect of chronic kidney disease and comorbid conditions on healthcare costs: A 10-year observational study in a general population. Am J Nephrol 2010; 31:222-229.
12. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med 2009; 150:795-802.
13. Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res 2011; 109:463-474.
14. Tabb DL, Vega-Montoto L, Rudnick PA, et al. Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res 2010; 9:761-776.
15. Kleinbaum DG. Applied regression analysis and other multivariable methods. 4th ed. Australia; Belmont, CA: Brooks/Cole; 2007. p 906.
16. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-1305.
17. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
18. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423-429.
19. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006; 17:1444-1452.
20. Tonelli M, Jose P, Curhan G, et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332:1426.
21. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305:1553-1559.
22. Peralta CA, Katz R, Sarnak MJ, et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. J Am Soc Nephrol 2011; 22:147-155.
23. Peralta CA, Shlipak MG, Judd S, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011; 305:1545-1552.
24. Fox CS, Gona P, Larson MG, et al. A multimarker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 2010; 21:2143-2149.
25. Fassett RG, Venuthurupalli SK, Gobe GC, et al. Biomarkers in chronic kidney disease: a review. Kidney Int 2011; 80:806-821.
26. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin dial 2009; 22:636-643.
27. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20:662-668.
28. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
29. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19:1154-1160.
30. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2005; 45:324-333.
31. Barreto DV, Barreto FC, Liabeuf S, et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and predialysis patients with chronic kidney disease. Kidney Int 2010; 77:550-556.
32. Vickery S, Webb MC, Price CP, et al. Prognostic value of cardiac biomarkers for death in a nondialysis chronic kidney disease population. Nephrol Dial Transplant 2008; 23:3546-3553.
33. Porazko T, Kuzniar J, Kusztal M, et al. Increased aortic wall stiffness associated with low circulating fetuin A and high C-reactive protein in predialysis patients. Nephron Clin Pract 2009; 113:c81-c87.
34. Hickman PE, McGill DA, Talaulikar G, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Intern Med J 2009; 39:812-818.
35. Paniagua R, Ventura MD, Avila-Diaz M, et al. NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant 2010; 25:551-557.
36. McGill D, Talaulikar G, Potter JM, et al. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysisdependent chronic renal failure. Clin Chim Acta 2010; 411:936-939.
37. Wang AY, Lam CW, Chan IH, et al. Sudden cardiac death in end-stage renal disease patients: a 5-year prospective analysis. Hypertension 2010; 56:210-216.
38. Desai AS, Toto R, Jarolim P, et al. Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD. Am J Kidney Dis 2011; 58:717-728.
39. Martens CR, Edwards DG. Peripheral vascular dysfunction in chronic kidney disease. Cardiol Res Pract 2011; 2011:267257.
40. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339:572-575.
41. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16:2456-2461.
42. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16:2449-2455.
43. Young JM, Terrin N, Wang X, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1115-1120.
44. Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis 2005; 12:353-365.
45. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6:643-656.
46. Cottone S, Nardi E, Mule G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol 2007; 67:209-216.
47. Yeo ES, Hwang JY, Park JE, et al. Tumor necrosis factor (TNF-alpha) and Creactive protein (CRP) are positively associated with the risk of chronic kidney disease in patients with type 2 diabetes. Yonsei Med J 2010; 51:519-525.
48. Levin A, Rigatto C, Barrett B, et al. Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events: CANPREDDICT: biomarkers improve prediction of one year outcomes in chronic kidney cohort. Nephrol Dial Transplant 2012; 27 (S2):ii63.
49. Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983-3989.
50. Yilmaz MI, Sonmez A, Saglam M, et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int 2010; 78:679-685.
51. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305:2432-2439.
52. Nasrallah MM, El-Shehaby AR, Salem MM, et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25:2679-2685.
53. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584-592.
54. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344:947-954.
55. Simon T, Opelz G, Wiesel M, et al. Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant 2003; 3:1121-1127.
56. Vasconcellos LM, Schachter AD, Zheng XX, et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66:562-566.
57. De Serres SA, Mfarrej BG, Grafals M, et al. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol 2012; 7:1018-1025.
58. Kaden J, Priesterjahn R. Increasing urinary IL-6 levels announce kidney graft rejection. Transpl Int 2000; 13 (Suppl 1):S34-S41.
59. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353:2342-2351.
60. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J Am Soc Nephrol 2010; 21:646-653.
61. O'Riordan E, Orlova TN, Mei JJ, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004; 15:3240-3248.
62. Reichelt O, Muller J, von Eggeling F, et al. Prediction of renal allograft rejection by urinary protein analysis using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry). Urology 2006; 67:472-475.
63. Peng W, Chen J, Jiang Y, et al. Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine. Nephrology (Carlton) 2008; 13:73-79.
64. Alakulppi NS, Kyllonen LE, Partanen J, et al. Diagnosis of acute renal allograft rejection by analyzing whole blood mRNA expression of lymphocyte marker molecules. Transplantation 2007; 83:791-798.
65. Dong W, Shunliang Y, Weizhen W, et al. Prediction of acute renal allograft rejection in early posttransplantation period by soluble CD30. Transpl Immunol 2006; 16:41-45.
66. Kamali K, Abbasi MA, Farokhi B, et al. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp Clin Transplant 2009; 7:237-240.
67. Manfro RC, Aquino-Dias EC, Joelsons G, et al. Noninvasive Tim-3 messenger RNA evaluation in renal transplant recipients with graft dysfunction. Transplantation 2008; 86:1869-1874.
68. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65:2390-2397.
69. Ting YT, Coates PT, Marti HP, et al. Urinary soluble HLA-DR is a potential biomarker for acute renal transplant rejection. Transplantation 2010; 89:1071-1078.
70. Dubinski B, Boratynska M, Kopec W, et al. Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)-sensitive rejection markers in renal graft recipients. Transpl Immunol 2008; 18:203-207.
71. Calabuig AS, Guirado L, Ramos D. Prognostic significance and diagnosis of proteinuria in renal transplantation. Transplant Rev (Orlando) 2012; 26:30-35.
72. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010; 77:44-50.
73. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4:1246-1254.
74. Dahle DO, MjoenG, Oqvist B, et al. Inflammation-associated graft loss in renal transplant recipients. Nephrol Dial Transplant 2011; 26:3756-3761.
75. Winkelmayer WC, Lorenz M, Kramar R, et al. C-reactive protein and body mass index independently predict mortality in kidney transplant recipients. Am J Transplant 2004; 4:1148-1154.
76. Winkelmayer WC, Schaeffner ES, Chandraker A, et al. A J-shaped association between high-sensitivity C-reactive protein and mortality in kidney transplant recipients. Transpl Int 2007; 20:505-511.
77. Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004; 66:441-447.
78. Oterdoom LH, de Vries AP, van Ree RM, et al. N-terminal pro-B-type natriuretic peptide and mortality in renal transplant recipients versus the general population. Transplantation 2009; 87:1562-1570.
79. Connolly GM, Cunningham R, McNamee PT, et al. Troponin T is an independent predictor of mortality in renal transplant recipients. Nephrol Dial Transplant 2008; 23:1019-1025.
80. Ducloux D, Courivaud C, Bamoulid J, et al. Pretransplant serum vitamin D levels and risk of cancer after renal transplantation. Transplantation 2008; 85:1755-1759.
81. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005; 26:662-687.
82. Wolf M, Molnar MZ, Amaral AP, et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011; 22:956-966.
83. Yilmaz MI, Sonmez A, Saglam M, et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008; 19:388-395.
84. Islam M, Burke JF Jr, McGowan TA, et al. Effect of antitransforming growth factor-beta antibodies in cyclosporine-induced renal dysfunction. Kidney Int 2001; 59:498-506.
85. Ling H, Li X, Jha S, et al. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 2003; 14:377-388.
86. Xin J, Homma T, Matsusaka T, et al. Suppression of cyclosporine A nephrotoxicity in vivo by transforming growth factor beta receptor- immunoglobulin G chimeric protein. Transplantation 2004; 77:1433-1442.
87. Shihab FS, Yi H, Bennett WM, et al. Effect of nitric oxide modulation on TGFbeta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int 2000; 58:1174-1185.
88. Seiler S, Reichart B, Roth D, et al. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010; 25:3983-3989.
89. Autier P, Gandini S. Vitamin D supplementation and total mortality: a metaanalysis of randomized controlled trials. Arch Intern Med 2007; 167:1730-1737.
90. Andrade J, Er L, Ignaszewski A, et al. Exploration of association of 1,25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol 2008; 3:1800-1806.
91. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005; 68:1973-1981.